TissueScan, Cancer Survey cDNA Array 384 - I

SKU
CSRT302
TissueScan Cancer Survey Panel 384 - I, containing five identical sets of 381 tissues covering twenty two (22) different cancers
  $3,740.00
In Stock*
Specifications
Specifications
Product Data
TissueScan Type Cancer Survey
Array Name Cancer Survey cDNA Array 384 - I
Clinical Info
Diagnosis Category Multiple
Tissue Multiple
Shipping Ambient
Description TissueScan Cancer Survey Panel 384 - I, containing five identical sets of 381 tissues covering twenty two (22) different cancers
Reviews
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin
Li, Shan, Chen et al
Cell Metab. (2019) 30 (2), 319-328.e8 DOI: 10.1016/j.cmet.2019.05.022
AI Summary: OriGene’s Human cDNA Array products (CSRT101, CSRT302, HMRT104, HBRT301) were used in this study to analyze gene expression across various human tissues, supporting the identification and characterization of OLFR734 as the receptor for Asprosin.
Snippet: Skip to article;Biological Samples Human cDNA Array OriGene CSRT101, CSRT302, HMRT104, HBRT301 cDNA, human adult normal tissue BioChain C1234063-10
Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness
Hesse, Schröder, Brandt et al
JCI Insight (2019) 5 DOI: 10.1172/jci.insight.125543
AI Summary: OriGene’s sclerostin siRNA was used to specifically knock down sclerostin expression in breast cancer cells, enabling the study to assess the role of sclerostin in bone metastases and muscle weakness.
Snippet: MDA-MB-231 cells were transfected with scrambled control siRNA or siRNA against sclerostin (Origene) using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. For collection of conditioned medium, MDA-MB-231 cells were cultured in the presence of 1% FBS for 24 hours, and conditioned medium was collected and stored at –80°C. Osteoblast differentiation was ind...
Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer
Gangadharan, Nyirenda, Patel et al
Breast (2018) 39, 101-109 DOI: 10.1016/j.breast.2018.03.015
AI Summary: OriGene’s TissueScan Cancer Survey Panel and Breast Cancer Panel I-IV were used in this study to screen and analyze gene expression levels, including PIP, across a wide range of human cancer and breast cancer tissue samples.
Snippet: TissueScan Cancer Survey Panel (OriGene) was used for screening 18 different human cancer types (over 380 biospecimens), and Breast Cancer Panel I-IV (OriGene) was used for determining the expression levels of genes (approximately 150 biospecimens)
Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer
Taniguchi, Hoshino, Moriya et al
Oncotarget (2017) 8 (29), 46856-46874 DOI: 10.18632/oncotarget.16776
Snippet: We analyzed the RT2 Pro ler PCR Arrays (QIAGEN, Hilden, Germany) and the Cancer Survey cDNA array or Breast Cancer cDNA array (OriGene, Rockville, MD, USA) to detect mRNA using qRT- PCR with CYBR Green and a ViiA7 System (Life Technologies, Carlsbad, CA, USA)
FigureFigureFigure
TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1
Wang, Liu, Qiu et al
Oncogenesis (2017) 6 (4), e323 DOI: 10.1038/oncsis.2017.18
AI Summary: OriGene’s TissueScan Cancer and Normal Tissue cDNA Arrays were used in this study to quantitatively analyze TCRP1 gene expression across various human cancer and normal tissue samples.
Snippet: To examine the gene expression levels for TCRP1 in different cancer patient tissue samples, we performed quantitative PCR analysis on TissueScan Cancer and Normal Tissue cDNA Arrays (Origene Company, Rockville, MD, USA), which include 392 cases from different ... All 3 versions Cite SaveSaving
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer
Kokabee, Wang, Sevinsky et al
Cancer Biol. Ther. (2015)
Cited by 43
AI Summary: OriGene’s TissueScan Cancer Survey Panel (CSRT302) was used to measure BTK-A and BTK-C mRNA expression in human prostate cancer and lymphoma tissue samples, enabling the study’s analysis of BTK isoform expression in prostate tumors.
Snippet: …Measurement of BTK-A and BTK-C mRNA expression in prostate tumor tissues was performed using an array of first strand complementary DNA (cDNA) from human prostate cancer tissues and lymphoma samples contained in the TissueScan Cancer Survey Panel (CSRT302) in 384-well plates from OriGene (Rockville, MD)
Showing 1-6 of 6 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products